163 related articles for article (PubMed ID: 37841252)
1. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
2. A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Erikstad KI; Herdlevaer I; Peter E; Haugen M; Totland C; Vedeler C
Eur J Neurol; 2023 Jun; 30(6):1727-1733. PubMed ID: 36912432
[TBL] [Abstract][Full Text] [Related]
3. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M; Haugen M; Thorsteinsdottir M; Stefansson I; Salvesen HB; Storstein A; Vedeler CA
Cancer Immunol Immunother; 2017 Nov; 66(11):1463-1471. PubMed ID: 28710511
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Herdlevær I; Haugen M; Mazengia K; Totland C; Vedeler C
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531379
[TBL] [Abstract][Full Text] [Related]
5. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
6. Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
Herdlevaer I; Kråkenes T; Schubert M; Vedeler CA
Ann Clin Transl Neurol; 2020 Nov; 7(11):2231-2242. PubMed ID: 33009713
[TBL] [Abstract][Full Text] [Related]
7. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
Kråkenes T; Herdlevaer I; Raspotnig M; Haugen M; Schubert M; Vedeler CA
Ann Neurol; 2019 Aug; 86(2):316-321. PubMed ID: 31148214
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Panja D; Vedeler CA; Schubert M
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):141-156. PubMed ID: 29679372
[TBL] [Abstract][Full Text] [Related]
9. Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue.
Raspotnig M; Kråkenes T; Herdlevær I; Haugen M; Vedeler C
J Neuroimmunol; 2022 Jan; 362():577766. PubMed ID: 34823119
[TBL] [Abstract][Full Text] [Related]
10. Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy.
Bartley CM; Parikshak NN; Ngo TT; Alexander JA; Zorn KC; Alvarenga BA; Kang MK; Pedriali M; Pleasure SJ; Wilson MR
Front Neurol; 2021; 12():728700. PubMed ID: 34744969
[TBL] [Abstract][Full Text] [Related]
11. A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model.
Faure F; Yshii L; Renno T; Coste I; Joubert B; Desestret V; Liblau R; Honnorat J
Cerebellum; 2024 Feb; 23(1):181-196. PubMed ID: 36729270
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Schubert M; Panja D; Haugen M; Bramham CR; Vedeler CA
Acta Neuropathol; 2014 Dec; 128(6):835-52. PubMed ID: 25341622
[TBL] [Abstract][Full Text] [Related]
13. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
14. Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration.
Stich O; Graus F; Rasiah C; Rauer S
J Neuroimmunol; 2003 Aug; 141(1-2):165-9. PubMed ID: 12965268
[TBL] [Abstract][Full Text] [Related]
15. Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration.
Probst C; Komorowski L; de Graaff E; van Coevorden-Hameete M; Rogemond V; Honnorat J; Sabeter L; Graus F; Jarius S; Voltz R; Wildemann B; Franciotta D; Blöcker IM; Schlumberger W; Stöcker W; Sillevis Smitt PA
Neurol Neuroimmunol Neuroinflamm; 2015 Apr; 2(2):e68. PubMed ID: 25745634
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M; Treilleux I; Couillault C; Pissaloux D; Picard G; Paindavoine S; Attignon V; Wang Q; Rogemond V; Lay S; Ray-Coquard I; Pfisterer J; Joly F; Du Bois A; Psimaras D; Bendriss-Vermare N; Caux C; Dubois B; Honnorat J; Desestret V
Acta Neuropathol; 2018 Apr; 135(4):569-579. PubMed ID: 29299667
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Rojas-Marcos I; Picard G; Chinchón D; Gelpi E; Psimaras D; Giometto B; Delattre JY; Honnorat J; Graus F
Neuro Oncol; 2012 Apr; 14(4):506-10. PubMed ID: 22351748
[TBL] [Abstract][Full Text] [Related]
18. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers.
Greenlee JE; Clawson SA; Hill KE; Wood B; Clardy SL; Tsunoda I; Carlson NG
PLoS One; 2015; 10(4):e0123446. PubMed ID: 25885452
[TBL] [Abstract][Full Text] [Related]
19. CDR2 and CDR2L Yo Antigens in Paraneoplastic Cerebellar Degeneration.
Greenlee JE; Carlson NG
Ann Neurol; 2020 Aug; 88(2):428. PubMed ID: 32445212
[No Abstract] [Full Text] [Related]
20. High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display.
O'Donovan B; Mandel-Brehm C; Vazquez SE; Liu J; Parent AV; Anderson MS; Kassimatis T; Zekeridou A; Hauser SL; Pittock SJ; Chow E; Wilson MR; DeRisi JL
Brain Commun; 2020; 2(2):fcaa059. PubMed ID: 32954318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]